The aRTegenTM E2A-PBX1 quantitative qPCR kit is intended for quantitation of E2A-PBX1 (TCF3-PBX1 or t(1;19) (q23;p13)) fusion gene transcripts in peripheral blood or bone marrow samples.
Cat No: 731803
Key Features
- Detect and quantify E2A-PBX1 (TCF3-PBX1 or t(1;19) (q23;p13)) fusion gene transcripts.
- FAM and VIC/HEX probe-based detection system
- Capable of detecting less than 10 copies of E2A-PBX1 and ABL transcripts
- Separate optimization of Reverse transcription and qPCR steps and ability to generate cDNA stock for further use.
- Two step qPCR reaction enable the test to be highly sensitive and to work well with limited sample amount
Acute lymphoblastic leukemia (ALL) is a hematologic neoplasia occurring at a frequency of 3 to 5% and characterized with the proliferation of immature lymphoid cells in bone marrow, peripheral blood, and other organs. The recurring chromosomal translocation t(1;19) is well-known ALL specific cytogenetic alteration and cause fusion of the transcription factor 3 gene (TCF3, previously E2A) at 19p13 with the pre-B cell leukemia homeobox 1 gene (PBX1) at 1q23 to form TCF3-PBX1 transcripts. This assay can be used for detection and quantification of TCF3‐PBX1 fusion transcripts for monitoring transcript levels.
The aRTegenTM E2A-PBX1 quantitative qPCR kit is for Research Use Only and not for diagnostic use.
